Skip to content

Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction

Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction (ECLIPSE-HF)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05209919
Acronym
ECLIPSE-HF
Enrollment
400
Registered
2022-01-27
Start date
2021-11-11
Completion date
2024-12-01
Last updated
2022-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Tricuspid Regurgitation

Keywords

tricuspid regurgitation; heart failure

Brief summary

Purpose Functional tricuspid regurgitation (FTR) has been shown to be associated with increased morbidity and mortality in several clinical conditions, including heart failure (HF) with reduced left ventricular ejection fraction as well as pulmonary arterial hypertension (PAH). We have designed a study aiming at: characterizing the echocardiographic morphology of the tricuspid valve apparatus and the pathophysiology of FTR in heart failure with reduced, mid-range or preserved left ventricular ejection fraction (HFrEF, HFmrEF, HFpEF) and in PAH patients; correlating the morphologic characteristics of tricuspid valve apparatus with hemodynamic severity of FTR; correlating the severity of FTR with the clinical condition and outcome. Methods The study will be a non-interventional, prospective, international, multicenter, longitudinal study. The minimum number of patients which are expected to be enrolled is 300 HF patients, including HFrEF, HFmrEF and HFpEF patients, whereas 100 PAH patients will serve as control. The patients will be enrolled in 20 centers in Europe, North America and Saudi Arabia. The echocardiographic parameters will be analyzed by the local investigators; a quality control committee will evaluate all data entered in the database to identify potential outliers and a random sample of 10% of cases will be blindly re-analysed in a central core-lab. Conclusions This study has been designed to improve our understanding of pathophysiological mechanisms and clinical relevance of FTR across all HF phenotypes. The results could potentially allow a more appropriate selection of heart failure patients with FTR for tricuspid valve intervention by percutaneous or surgical repair or replacement.

Interventions

DIAGNOSTIC_TESTTransthoracic Echocardiography

All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)

Sponsors

Cardarelli Hospital
CollaboratorOTHER
Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy
CollaboratorOTHER_GOV
Monaldi Hospital
CollaboratorOTHER
Federico II University
CollaboratorOTHER
Cava de Tirreni Costiera Amalfitana Hospital Salerno
CollaboratorUNKNOWN
Umberto I Hospital, Nocera Inferiore
CollaboratorOTHER
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona
CollaboratorOTHER
Azienda Ospedaliera S. Maria della Misericordia
CollaboratorOTHER
University of Pisa
CollaboratorOTHER
Niguarda Hospital
CollaboratorOTHER
IRCCS Policlinico S. Donato
CollaboratorOTHER
University of Parma
CollaboratorOTHER
University of Siena
CollaboratorOTHER
Foligno Hospital
CollaboratorOTHER
University of Targu Mures, Romania
CollaboratorOTHER
Szeged University
CollaboratorOTHER
National Cardiology Hospital, Bulgaria
CollaboratorOTHER
Bieganski Hospital Lodz, Poland
CollaboratorUNKNOWN
Departement of clinical sciences, Lund University and Skane University Hospidal, Lund Sweden
CollaboratorUNKNOWN
King Faisal Specialist Hospital & Research Center
CollaboratorOTHER
Piedmont Heart Institute, Inc., Atlanta, GA
CollaboratorINDUSTRY
Jewish General Hospital
CollaboratorOTHER
Ospedali Riuniti di Foggia
CollaboratorOTHER
Fondazione IRCCS Policlinico San Matteo di Pavia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* consecutive consenting outpatients with HFrEF, HFmrHF, HFpEF or PAH, * ambulatory visit routinely planned with an echocardiographic examination, * at the time of the visit at least moderate FTR diagnosed at echocardiography (by visual assessment), * aged ≥ 18 years old, * capable to sign an informed consent.

Exclusion criteria

* age \< 18 years old, * congenital heart disease, * heart failure due to organic mitral or aortic valve disease. No examination will be performed in addition to what is routinely planned for patients' evaluation.

Design outcomes

Primary

MeasureTime frame
Time to all-cause death or to first HF hospitalization12 months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026